Blue Cross Blue Shield of Massachusetts and the state Division of Insurance struck a stipulation agreement clearing a nearly 12% “merged market” premium hike for 2026.
The move follows weeks of friction after regulators initially rejected the insurer’s filing as excessive and out of line with state law.
The deal pulls back the regulator’s disapproval letter and cancels BCBS’s request for a hearing. Company reps said the increase reflects surging medical costs, with roughly 90% of premium dollars now funneled straight into doctor visits, prescriptions, and procedures.
“No health plan wants to raise premiums at this pace,” spokesperson Kelsey Pearse wrote in an email, noting the decision aims to give policyholders predictability for 2026.
She said the insurer is also working with policymakers to find longer-term ways to keep coverage affordable.
Medical and drug costs are rising at the fastest clip in over a decade, the company said. A key culprit: GLP-1 weight loss drugs.
In 2024, BCBS spent more than $300mn on five of these treatments, labeling the price tags unsustainable. The carrier confirmed it will stop covering GLP-1s for weight loss in 2026, trimming its rate request by 3%.
